Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2011-03-29
2011-03-29
Foley, Shanon A (Department: 1619)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C604S020000
Reexamination Certificate
active
07914815
ABSTRACT:
Embodiments of the present invention relate to a method for delivering pharmaceuticals to the lens of the eye to treat or prevent presbyopia. According to the embodiments, pharmaceuticals may be applied by providing the pharmaceuticals to the eye and promoting delivery of the pharmaceuticals into the lens capsule and/or lens fibers of the lens of the eye. Methods include iontophoresis, nano-medication, and photonic activation to deliver the pharmaceuticals to treat or prevent presbyopia.
REFERENCES:
patent: 3238224 (1966-03-01), Ohara et al.
patent: 3855240 (1974-12-01), Mueller
patent: 4210667 (1980-07-01), Sarges et al.
patent: 4755528 (1988-07-01), DuPriest et al.
patent: 5395356 (1995-03-01), King et al.
patent: 5459133 (1995-10-01), Neufeild
patent: 5465737 (1995-11-01), Schachar
patent: 5466680 (1995-11-01), Rudy
patent: 5476515 (1995-12-01), Kelman
patent: 5488050 (1996-01-01), Neufeld
patent: 5503165 (1996-04-01), Schachar
patent: 5527774 (1996-06-01), Girard
patent: 5529076 (1996-06-01), Schachar
patent: 5624955 (1997-04-01), Nagasawa et al.
patent: 5665770 (1997-09-01), Terao et al.
patent: 5686450 (1997-11-01), Hellberg et al.
patent: 5688828 (1997-11-01), Hellberg et al.
patent: 5691379 (1997-11-01), Ulrich et al.
patent: 5722952 (1998-03-01), Schachar
patent: 5817630 (1998-10-01), Hoffmann et al.
patent: 5843184 (1998-12-01), Cionni
patent: 5869468 (1999-02-01), Freeman
patent: 5874455 (1999-02-01), Terao et al.
patent: 5888243 (1999-03-01), Silverstrini
patent: 6007510 (1999-12-01), Nigam
patent: 6013462 (2000-01-01), Kauvar et al.
patent: 6030950 (2000-02-01), Ohlenschlager
patent: 6063116 (2000-05-01), Kelleher
patent: 6214044 (2001-04-01), Silverstrini
patent: 6313164 (2001-11-01), Fujita et al.
patent: 6339102 (2002-01-01), Meyerhoff et al.
patent: 6387945 (2002-05-01), Packer et al.
patent: 6472541 (2002-10-01), Tsien et al.
patent: 6664287 (2003-12-01), Avery et al.
patent: 6703039 (2004-03-01), Xia et al.
patent: 6743779 (2004-06-01), Unger et al.
patent: 6923955 (2005-08-01), Till et al.
patent: 7164943 (2007-01-01), Roy
patent: 2002/0035243 (2002-03-01), Imfeld et al.
patent: 2003/0187058 (2003-10-01), Hasselwander et al.
patent: 2003/0228299 (2003-12-01), Droy-Lefaix et al.
patent: 2004/0044227 (2004-03-01), Klatt et al.
patent: 2004/0092586 (2004-05-01), Ogata et al.
patent: 2005/0101677 (2005-05-01), Till
patent: 2005/0112113 (2005-05-01), Till et al.
patent: 2005/0130881 (2005-06-01), Shashoua et al.
patent: 2005/0137124 (2005-06-01), Castillejos
patent: 2005/0171212 (2005-08-01), Gierhart et al.
patent: 2006/0177430 (2006-08-01), Bhushan
patent: 2006/0188492 (2006-08-01), Richardson et al.
patent: 2007/0055070 (2007-03-01), Lawrence
patent: 2007/0207116 (2007-09-01), Brown
patent: 2007/0293562 (2007-12-01), Mylari et al.
patent: 2008/0038316 (2008-02-01), Wong et al.
patent: 2008/0139990 (2008-06-01), Till et al.
patent: 2008/0213239 (2008-09-01), Morris
patent: 2009/0082281 (2009-03-01), Shashoua
patent: 2009/0093541 (2009-04-01), Ogata
patent: 2009/0124683 (2009-05-01), Garner et al.
patent: 2009/0192212 (2009-07-01), Garner et al.
patent: 2009/0227677 (2009-09-01), Garner et al.
patent: 2010/0098653 (2010-04-01), Yu et al.
patent: 0 369 880 (1990-05-01), None
patent: WO 93/25166 (1993-12-01), None
patent: WO 94/01773 (1994-01-01), None
patent: WO 02/13863 (2002-02-01), None
patent: WO 2003/084532 (2003-10-01), None
patent: WO 2004/028536 (2004-04-01), None
patent: WO 2008/120070 (2008-10-01), None
Bron, A.J., et al. “The Ageing Lens” Ophthalmologica (2000) 214(1):86-104.
Hoenders, H.J., et al. “Lens proteins and aging” J Gerontol (May 1983) 38(3):278-86.
Moffat, B.A., et al. “Age-related Changes in the Kinetics of Water Transport in Normal Human Lenses” Exp. Eye Res. (1999) 69(6):663-69.
Phelps-Brown, N.A., et al. “Nutritional supplements and the eye” Eye (1998) 12:127-33.
Spector, A., et al. “Thioredoxin fragment 31-36 is reduced by dihydrolipoamide and reduces oxidized protein” Biochem Biophys Res Commun (Jan. 1988) 150(1):156-62.
Krumdieck et al., “Mechanism of Homocysteine Toxicity on Connective Tissues: Implication for the Morbidity of Aging,” J. Nutr. 2000, 130 (2S suppl): 365S-368S.
Krueger, M.D., M.S.E., Ronald R., et al., “Experimental increase in accommodative potential after neodymium: yttrium-aluminum-garnet laser photodisruption of paired cadaver lenses,” Ophthalmology (2001), pp. 108: 2122-2129.
Giblin FJ, et al. 1979, The effects of X-irradiation on lens reducing systems, Investigative Ophthalmology & Visual Science 18:468-475.
Kramar P, et al. 1987. Thermal cataract formation in rabbits. NCBI Pubmed abstract, PMID: 3426637, abstract of Bioelectromagnetics 8:397-406.
Lipman RM, et al. 1988, Cataracts induced by Microwave and Ionizing Radiation. NCBI Pubmed abstract, PMID: 3068822, abstract of Surv. Ophthalmol 33:200-210.
Newell, 1996. Ophthalmology: Principles and Concepts St. Louis: Mosby-Year Book St. Louis, p. 83.
Halhal M, et al. 2004. Iontophoresis: from the lab to the bed side. Exp Eye Res 78(3):751-57.
Lee V & Bundgaard H. 1992. Improved Ocular Drug Delivery with Prodrugs. In: Sloan:K. ed. Produgs: Topical and Ocular Drug Delivery, vol. 53, p. 233.
Sarraf D & Lee DA. 1994. The Role of Iontophoresis in Ocular Drug Delivery. J Ocul Pharmacol 10(1):69-81.
U.S. Appl. No. 12/815,586, filed Jun. 15, 2010, Garner et al.
U.S. Appl. No. 12/815,526, filed Jun. 15, 2010, Garner et al.
Aloisi et al. 1948. Glycerylphosphorylcholine and Choline Glycerophosphate. Biochemical Journal. vol. 43, pp. 157-161; p. 157, col. 1, para 2-3; col. 2, para 1; p. 158, col. 1, para 4.
Al-Ghoul, K. J., R. K. Nordgren, A. J. Kuszak, C. D. Freel, M. J. Costello, and J. R. Kuszak. 2001. Structural evidence of human nuclear fiber compaction as a function of ageing and cataractogenesis.Experimental eye research72: 199-214.
Applegate, M. A., K. M. Humphries, and L. I. Szweda. 2007. Reversible Inhibition of alpha-Ketoglutarate Dehydrogenase by Hydrogen Peroxide: Glutathionylation and Protection of Lipoic Acid.Biochemistry.
Argirova, M., M. Kleine-Reidick, and W. Breipohl. 2004. Redox status of the eye lens: a regional study.Cell biochemistry and biophysics41: 381-390.
Ariga T, et al. 2000. Antithrombotic and antineoplastic effects of phyto-organosulfur compounds. Biofactors. 13(1-4):251-5.
Arora A, et al. 2004. Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver. Carcinogenesis. 25(6):941-9. Epub Jan. 16, 2004.
Asmellash S, et al. 2005. Modulating the endoplasmic reticulum stress response with trans-4,5-dihydroxy-1,2-dithiane prevents chemically induced renal injury in vivo. Toxicol Sci. 88(2):576-84. Epub Sep. 8, 2005.
Baghieri, S. and M. H. Garner. 1992. Na,K-ATPase and phospholipid degradation in bovine and human lenses.Current eye research11: 459-467.
Belloir C, et al. 2006. Protective effects of garlic sulfur compounds against DNA damage induced by direct- and indirect-acting genotoxic agents in HepG2 cells. Food Chem Toxicol. 44(6):827-34.
Bilska, A., and L. Wlodek. 2005. Lipoic acid—the drug of the future? PharmacolRep57: 570-577.
Bilska, A., M. Dubiel, M. Sokolowska-Jezewicz, E. Lorenc-Koci, and L. Wlodek. 2007. Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex of rat brain.Neuroscience146: 1758-1771.
Bitar, M. S., S. Wahid, C. W. Pilcher, E. Al-Saleh, and F. Al-Mulla. 2004. Alpha-lipoic acid mitigates insulin resistance in Goto-Kakizaki rats.Hormone and metabolic research. Hormon- und Stoffwechselforschung36: 542-549.
Blanco, R. A., T. R. Ziegler, B. A. Carlson, P. Y. Cheng, Y. Park, G. A. Cotsonis, C. J. Accardi, and D. P. Jones. 2007. Diurnal variation in glutathione and cysteine redox states in human plasma.The American journal of clinical nutrition86: 1016-1023.
Blankenship, T. N., J. F. Hess, and P. G. FitzGerald. 2001. Development- and differentiation-dependent reorganization of intermediate filament
Blum Ronald D.
Duston Dwight P.
Kokonaski William
Till Jonathan S.
Encore Health, LLC
Foley Shanon A
Kilpatrick Townsend & Stockton LLP
LandOfFree
Method for delivery of pharmaceuticals for treating or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for delivery of pharmaceuticals for treating or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for delivery of pharmaceuticals for treating or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2685594